Scotland’s NHS to fund Roche’s Hemlibra in haemophilia ANHS patients in Scotland with haemophilia A are set to get access to Roche and Chugai’s prophylactic injection Share XScotland’s NHS to fund Roche’s Hemlibra in haemophilia Ahttps://pharmaphorum.com/news/scotlands-nhs-to-fund-roches-hemlibra-in-haemophilia-a/
FDA takes another step to encourage copycat insulin productsThe FDA has made another move to allow biosimilars get to market in the US more quickly, this Share XFDA takes another step to encourage copycat insulin productshttps://pharmaphorum.com/news/fda-takes-another-step-to-encourage-copycat-insulin-products/
AZ’s Lynparza inches towards ‘game changer’ okay in pancreatic cancerAstraZeneca and Merck & Co are closer to a new use for their PARP inhibitor Lynparza in pancreatic Share XAZ’s Lynparza inches towards ‘game changer’ okay in pancreatic cancerhttps://pharmaphorum.com/news/azs-lynparza-inches-towards-game-changer-okay-in-pancreatic-cancer/
Merck’s last-resort antibiotic Recarbrio nears EU approvalMerck & Co/MSD’s three-drug antibiotic Recarbrio has been recommended for approval in Europe for Gram-negative infections, but should Share XMerck’s last-resort antibiotic Recarbrio nears EU approvalhttps://pharmaphorum.com/news/mercks-last-resort-antibiotic-recarbrio-nears-eu-approval/
Novartis’ blockbuster hope Beovu clears EMA advisory panelNovartis could launch its new age-related macular degeneration drug in Europe early next year after getting a green Share XNovartis’ blockbuster hope Beovu clears EMA advisory panelhttps://pharmaphorum.com/news/novartis-blockbuster-hope-beovu-clears-ema-advisory-panel/
Pharma fury as Trump’s team reneges on biologic patent rules in trade talksA key part of president Donald Trump’s strategy to cut drug prices was to attack global “freeloading” for Share XPharma fury as Trump’s team reneges on biologic patent rules in trade talkshttps://pharmaphorum.com/news/pharma-fury-as-trumps-team-reneges-on-biologic-patent-rules-in-trade-talks/
UK’s NHS to fund Shionogi’s Mulpleo after backing from NICE and SMCShionogi’s Mulpleo for severely low levels of blood platelets caused by liver disease is to be made available Share XUK’s NHS to fund Shionogi’s Mulpleo after backing from NICE and SMChttps://pharmaphorum.com/news/uks-nhs-to-fund-shionogis-mulpleo-after-backing-from-nice-and-smc/
Scotland backs AZ’s Lynparza for first-line ovarian cancer maintenanceThe Scottish Medicines Consortium (SMC) has backed routine funding of AstraZeneca and MSD’s Lynparza as a maintenance treatment Share XScotland backs AZ’s Lynparza for first-line ovarian cancer maintenancehttps://pharmaphorum.com/news/scotland-backs-azs-lynparza-for-first-line-ovarian-cancer-maintenance/
ViiV presses go on FDA filing for first-in-class HIV drug fostemsavirViiV Healthcare has fulfilled its pledge of submitting its new HIV drug fostemsavir for approval before year end, Share XViiV presses go on FDA filing for first-in-class HIV drug fostemsavirhttps://pharmaphorum.com/news/viiv-presses-go-on-fda-filing-for-first-in-class-hiv-drug-fostemsavir/
